Bayer submits US regorafenib application in GIST
This article was originally published in Scrip
Executive Summary
Bayer HealthCare submitted its new drug application (NDA) to the US FDA for regorafenib as a treatment for patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment, the firm and its partner, Onyx Pharmaceuticals, said on 30 August.